Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rocbrutinib - Newave Pharmaceuticals

Next Previous
Drug Profile

Rocbrutinib - Newave Pharmaceuticals

Alternative Names: HS-10561; LP-168; NWP-775

Latest Information Update: 26 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Newave Pharmaceuticals
  • Developer Guangzhou Lupeng Pharmaceutical; Newave Pharmaceuticals
  • Class Alcohols; Alkenes; Amides; Aniline compounds; Antineoplastics; Cyclic ethers; Cyclopentanes; Eye disorder therapies; Ketones; Piperazines; Pyridines; Pyrroles; Skin disorder therapies; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Mantle-cell lymphoma
  • Phase III Chronic lymphocytic leukaemia
  • Phase II Diffuse large B cell lymphoma; Multiple sclerosis
  • Phase I/II B-cell lymphoma; Chronic urticaria
  • Phase I Marginal zone B-cell lymphoma
  • Preclinical Idiopathic thrombocytopenic purpura; Membranous glomerulonephritis
  • Discontinued Neuromyelitis optica

Most Recent Events

  • 20 Aug 2026 Guangzhou Lupeng Pharmaceutical Company initiates a phase II trial in Multiple sclerosis in China (PO) (NCT07776743)
  • 14 Jul 2026 Phase-I/II clinical trials in Chronic lymphocytic leukaemia (Combination therapy) in China (PO) (NCT07609862)
  • 14 Jul 2026 Phase-I/II clinical trials in B-cell lymphoma (Combination therapy) in China (PO) (NCT07609862)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top